Drug
Retigabine
Retigabine is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
75%(3 trials)
Phase Distribution
Ph phase_1
1
20%
Ph phase_2
1
20%
Ph phase_3
3
60%
Phase Distribution
1
Early Stage
1
Mid Stage
3
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
3(60.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
80.0%
4 of 5 finished
Non-Completion Rate
20.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(4)
Terminated(1)
Detailed Status
Completed4
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (20.0%)
Phase 21 (20.0%)
Phase 33 (60.0%)
Trials by Status
withdrawn120%
completed480%
Recent Activity
0 active trials
Showing 5 of 5
withdrawnphase_1
Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects
NCT01691872
completedphase_2
Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)
NCT00612105
completedphase_3
Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy
NCT00235755
completedphase_3
Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy
NCT00232596
completedphase_3
Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study
NCT01823159
Clinical Trials (5)
Showing 5 of 5 trials
NCT01691872Phase 1
Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects
NCT00612105Phase 2
Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)
NCT00235755Phase 3
Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy
NCT00232596Phase 3
Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy
NCT01823159Phase 3
Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5